Schering Sales Corp. to pay $435m in settlement

Share this article:
Schering Sales Corp., a division of Schering-Plough, will pay $435 million in connection with Medicaid fraud and illegal sales and marketing programs under a Jan. 17 court sentence.

A suit brought by the FDA and other agencies charged the company with making false statements to government agencies to hide its illegal off-label promotion of Temodar for use in treating brain tumors and metasteses and Intron A for use in treating superficial bladder cancer.

The suit also said Schering concealed its best price on Claritin RediTabs to avoid paying millions of dollars in additional Medicaid rebate liabilities.

The company pleaded guilty last September to criminal charges of making false statements to the FDA and to the HHSs. The company was sentenced to pay a $180 million criminal fine on those charges.

Schering pleaded guilty to conspiring with others to make false statements to the FDA in response to another inquiry by the agency.  

Share this article:
close

Next Article in News

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union